| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arbovirus Infections | 2 | 2018 | 104 | 0.77 | Why? |
| Communicable Diseases | 6 | 2019 | 2148 | 0.73 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2018 | 1475 | 0.70 | Why? |
| Therapeutic Human Experimentation | 1 | 2017 | 39 | 0.67 | Why? |
| Epidemics | 7 | 2020 | 6407 | 0.66 | Why? |
| Inappropriate Prescribing | 1 | 2020 | 284 | 0.66 | Why? |
| Research Design | 7 | 2021 | 5830 | 0.62 | Why? |
| Clinical Medicine | 1 | 2017 | 93 | 0.61 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.60 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.60 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.56 | Why? |
| Professional Competence | 1 | 2017 | 246 | 0.52 | Why? |
| Zika Virus Infection | 2 | 2018 | 1920 | 0.52 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.51 | Why? |
| Epidemiologic Methods | 1 | 2016 | 392 | 0.49 | Why? |
| Semen | 1 | 2017 | 550 | 0.46 | Why? |
| Biological Specimen Banks | 1 | 2019 | 1142 | 0.43 | Why? |
| Communicable Diseases, Emerging | 2 | 2017 | 2523 | 0.42 | Why? |
| Influenza, Human | 8 | 2020 | 10779 | 0.42 | Why? |
| Africa, Western | 3 | 2018 | 363 | 0.36 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2020 | 2984 | 0.33 | Why? |
| Viruses | 2 | 2017 | 2238 | 0.33 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2021 | 10649 | 0.32 | Why? |
| Antiviral Agents | 11 | 2021 | 41703 | 0.30 | Why? |
| Zika Virus | 1 | 2018 | 1924 | 0.28 | Why? |
| Enterovirus | 2 | 2018 | 402 | 0.27 | Why? |
| Biomedical Research | 3 | 2020 | 5270 | 0.26 | Why? |
| Enterovirus Infections | 2 | 2018 | 404 | 0.26 | Why? |
| Virus Diseases | 2 | 2017 | 3779 | 0.25 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.24 | Why? |
| Dexamethasone | 4 | 2021 | 2055 | 0.24 | Why? |
| Seroepidemiologic Studies | 4 | 2017 | 10017 | 0.24 | Why? |
| Glucocorticoids | 4 | 2021 | 4431 | 0.22 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.22 | Why? |
| Informed Consent | 2 | 2019 | 890 | 0.22 | Why? |
| Evidence-Based Emergency Medicine | 1 | 2020 | 48 | 0.21 | Why? |
| Severe Acute Respiratory Syndrome | 7 | 2020 | 12361 | 0.19 | Why? |
| Disease Outbreaks | 10 | 2020 | 27595 | 0.19 | Why? |
| Practice Guidelines as Topic | 2 | 2021 | 15421 | 0.19 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.18 | Why? |
| CD55 Antigens | 1 | 2017 | 14 | 0.18 | Why? |
| Humans | 62 | 2021 | 930598 | 0.17 | Why? |
| Teratogens | 1 | 2017 | 15 | 0.17 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.17 | Why? |
| Sierra Leone | 1 | 2018 | 267 | 0.17 | Why? |
| Coronavirus Infections | 19 | 2021 | 253789 | 0.17 | Why? |
| Arboviruses | 1 | 2018 | 76 | 0.17 | Why? |
| Refugee Camps | 1 | 2018 | 62 | 0.17 | Why? |
| Hand, Foot and Mouth Disease | 1 | 2018 | 115 | 0.17 | Why? |
| Strongyloides stercoralis | 1 | 2017 | 70 | 0.16 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.16 | Why? |
| Oxygen Inhalation Therapy | 2 | 2020 | 3629 | 0.16 | Why? |
| Strongyloidiasis | 1 | 2017 | 80 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.16 | Why? |
| Pandemics | 24 | 2021 | 389249 | 0.15 | Why? |
| Central Nervous System Infections | 1 | 2018 | 158 | 0.15 | Why? |
| Influenza A Virus, H7N9 Subtype | 2 | 2017 | 415 | 0.15 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2018 | 265 | 0.15 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 243 | 0.15 | Why? |
| Spermatozoa | 1 | 2018 | 244 | 0.14 | Why? |
| Microcephaly | 1 | 2017 | 181 | 0.14 | Why? |
| Vietnam | 7 | 2017 | 1665 | 0.14 | Why? |
| Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.14 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.14 | Why? |
| Sample Size | 1 | 2017 | 518 | 0.14 | Why? |
| Toll-Like Receptor 3 | 1 | 2017 | 391 | 0.14 | Why? |
| Hospitalization | 11 | 2021 | 54280 | 0.14 | Why? |
| Pneumonia, Viral | 17 | 2020 | 243684 | 0.14 | Why? |
| Betacoronavirus | 18 | 2020 | 204454 | 0.13 | Why? |
| Streptococcal Infections | 1 | 2017 | 255 | 0.13 | Why? |
| Pharynx | 2 | 2018 | 1544 | 0.13 | Why? |
| Cost-Benefit Analysis | 2 | 2021 | 2259 | 0.13 | Why? |
| Body Fluids | 1 | 2018 | 451 | 0.13 | Why? |
| Critical Care | 6 | 2021 | 14081 | 0.12 | Why? |
| Bibliometrics | 1 | 2020 | 731 | 0.12 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.12 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.12 | Why? |
| Global Health | 5 | 2020 | 13911 | 0.12 | Why? |
| Urbanization | 1 | 2013 | 133 | 0.12 | Why? |
| Livestock | 1 | 2013 | 184 | 0.12 | Why? |
| Asia, Southeastern | 1 | 2013 | 390 | 0.12 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.11 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.11 | Why? |
| Family Health | 1 | 2016 | 731 | 0.11 | Why? |
| Monitoring, Physiologic | 2 | 2021 | 1956 | 0.11 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| RNA-Binding Proteins | 1 | 2017 | 1022 | 0.10 | Why? |
| Agriculture | 1 | 2013 | 367 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.10 | Why? |
| Male | 28 | 2021 | 367725 | 0.09 | Why? |
| Odds Ratio | 2 | 2020 | 5861 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Respiration, Artificial | 7 | 2021 | 22116 | 0.09 | Why? |
| Drug Design | 1 | 2020 | 2627 | 0.09 | Why? |
| United Kingdom | 7 | 2021 | 18046 | 0.09 | Why? |
| Refugees | 1 | 2018 | 809 | 0.09 | Why? |
| Ecosystem | 1 | 2013 | 776 | 0.09 | Why? |
| Feces | 2 | 2018 | 4235 | 0.09 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2011 | 492 | 0.09 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2011 | 511 | 0.08 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| Drug Therapy, Combination | 4 | 2021 | 7268 | 0.08 | Why? |
| Female | 26 | 2021 | 380317 | 0.08 | Why? |
| Europe | 3 | 2018 | 12702 | 0.08 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.08 | Why? |
| Respiratory Tract Infections | 2 | 2018 | 6817 | 0.08 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.08 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.08 | Why? |
| Research | 1 | 2019 | 2115 | 0.08 | Why? |
| History, 21st Century | 1 | 2013 | 1849 | 0.08 | Why? |
| Aged | 20 | 2021 | 215776 | 0.07 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.07 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.07 | Why? |
| Family Characteristics | 1 | 2016 | 2551 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Risk Assessment | 5 | 2021 | 25439 | 0.07 | Why? |
| Civil Defense | 1 | 2017 | 1687 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Cohort Studies | 6 | 2020 | 36005 | 0.07 | Why? |
| Hospital Mortality | 7 | 2021 | 22087 | 0.07 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.07 | Why? |
| Epidemiological Monitoring | 2 | 2017 | 3493 | 0.07 | Why? |
| Treatment Failure | 2 | 2020 | 2106 | 0.07 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.07 | Why? |
| Commerce | 1 | 2013 | 1109 | 0.06 | Why? |
| Aged, 80 and over | 11 | 2021 | 88759 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Critical Illness | 3 | 2020 | 17281 | 0.06 | Why? |
| Infant | 7 | 2020 | 30274 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Case-Control Studies | 3 | 2017 | 17671 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Personnel, Hospital | 2 | 2006 | 2273 | 0.06 | Why? |
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 73 | 0.06 | Why? |
| Chromosomes, Human, Pair 19 | 1 | 2020 | 77 | 0.06 | Why? |
| Chromosomes, Human, Pair 12 | 1 | 2020 | 84 | 0.05 | Why? |
| Child, Preschool | 7 | 2020 | 36283 | 0.05 | Why? |
| Chromosomes, Human, Pair 21 | 1 | 2020 | 90 | 0.05 | Why? |
| TYK2 Kinase | 1 | 2020 | 116 | 0.05 | Why? |
| Receptors, CCR2 | 1 | 2020 | 103 | 0.05 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.05 | Why? |
| Infant, Newborn | 5 | 2020 | 23105 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Hydrocortisone | 2 | 2020 | 1790 | 0.05 | Why? |
| Animals | 4 | 2019 | 78931 | 0.05 | Why? |
| Equivalence Trials as Topic | 1 | 2020 | 242 | 0.05 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| 2',5'-Oligoadenylate Synthetase | 1 | 2020 | 205 | 0.05 | Why? |
| Vaccines | 1 | 2019 | 3692 | 0.05 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.05 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.05 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.05 | Why? |
| Injections, Intravenous | 1 | 2020 | 381 | 0.05 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.05 | Why? |
| Adult | 15 | 2021 | 244371 | 0.05 | Why? |
| England | 2 | 2021 | 5116 | 0.05 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.05 | Why? |
| Streptococcus suis | 1 | 2017 | 8 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2019 | 29620 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.04 | Why? |
| Travel | 3 | 2013 | 7220 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2021 | 511 | 0.04 | Why? |
| China | 6 | 2020 | 50654 | 0.04 | Why? |
| Russia | 1 | 2021 | 989 | 0.04 | Why? |
| Enterovirus D, Human | 1 | 2018 | 96 | 0.04 | Why? |
| Peer Review, Research | 1 | 2021 | 407 | 0.04 | Why? |
| Vestibular Diseases | 1 | 2017 | 68 | 0.04 | Why? |
| Cause of Death | 2 | 2021 | 4823 | 0.04 | Why? |
| Vertigo | 1 | 2017 | 141 | 0.04 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.04 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.04 | Why? |
| Meningitis, Bacterial | 1 | 2017 | 111 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Serogroup | 1 | 2018 | 510 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.04 | Why? |
| Italy | 1 | 2020 | 38444 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.04 | Why? |
| Databases, Factual | 2 | 2021 | 6248 | 0.04 | Why? |
| Enterovirus A, Human | 1 | 2018 | 180 | 0.04 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.04 | Why? |
| Disease Transmission, Infectious | 2 | 2017 | 9044 | 0.04 | Why? |
| Capsid Proteins | 1 | 2018 | 365 | 0.04 | Why? |
| Epidemiologic Studies | 1 | 2017 | 554 | 0.03 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| T-Lymphocytes | 1 | 2011 | 6670 | 0.03 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.03 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.03 | Why? |
| Child | 6 | 2020 | 70012 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Ebolavirus | 1 | 2020 | 834 | 0.03 | Why? |
| Surge Capacity | 1 | 2021 | 894 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Internationality | 1 | 2006 | 3297 | 0.03 | Why? |
| Asymptomatic Infections | 1 | 2011 | 7218 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Greece | 1 | 2018 | 2091 | 0.03 | Why? |
| Workflow | 1 | 2021 | 2373 | 0.03 | Why? |
| Disease Notification | 1 | 2017 | 639 | 0.03 | Why? |
| Public Health | 1 | 2016 | 16359 | 0.03 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 325 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Nasal Cavity | 1 | 2016 | 909 | 0.03 | Why? |
| Recovery of Function | 1 | 2021 | 2461 | 0.03 | Why? |
| Headache | 1 | 2021 | 2257 | 0.03 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.02 | Why? |
| Cross-Sectional Studies | 1 | 2016 | 53120 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.02 | Why? |
| Ventilators, Mechanical | 1 | 2021 | 2193 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 1439 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 11367 | 0.02 | Why? |
| Disaster Planning | 1 | 2021 | 1680 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.02 | Why? |
| Occupational Exposure | 1 | 2006 | 4742 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Cough | 1 | 2021 | 4891 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.02 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2006 | 9706 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.01 | Why? |
| Aircraft | 1 | 2006 | 498 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2011 | 51949 | 0.01 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.01 | Why? |
| Fomites | 1 | 2006 | 709 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Hospital Units | 1 | 2006 | 1017 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Hospitals, Public | 1 | 2004 | 774 | 0.01 | Why? |
| Ships | 1 | 2006 | 1046 | 0.01 | Why? |
| Hong Kong | 1 | 2006 | 3361 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
| Nursing Staff, Hospital | 1 | 2006 | 1554 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.01 | Why? |
| Virus Shedding | 1 | 2006 | 5834 | 0.01 | Why? |
| Occupational Diseases | 1 | 2004 | 2787 | 0.01 | Why? |
| Mass Screening | 1 | 2006 | 8005 | 0.00 | Why? |
| SARS Virus | 1 | 2006 | 13021 | 0.00 | Why? |
| Masks | 1 | 2004 | 8528 | 0.00 | Why? |
| Quarantine | 1 | 2006 | 18418 | 0.00 | Why? |